Nykode Therapeutics AS (NYKD.OL)

NOK 3.19

(-4.61%)

Market Cap (In NOK)

1.04 Billion

Revenue (In NOK)

12.9 Million

Net Income (In NOK)

-35.15 Million

Avg. Volume

1.91 Million

Currency
NOK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.55-21.4
PE
-
EPS
-
Beta Value
1.306
ISIN
NO0010714785
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael Thyring Engsig
Employee Count
-
Website
https://nykode.com
Ipo Date
2020-10-07
Details
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.